Skip to main content
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1989;67(6):731–736.

Purified equine rabies immune globulin: a safe and affordable alternative to human rabies immune globulin.

H Wilde, P Chomchey, P Punyaratabandhu, P Phanupak, S Chutivongse
PMCID: PMC2491311  PMID: 2633888

Abstract

Reported are the results of a retrospective study of 3156 patients who were treated at the Queen Saovabha Memorial Institute, Bangkok, with equine rabies immune globulin (ERIG). Only 51 patients (1.6%) exhibited serum-sickness-like reactions, none of which persisted for more than a week, and only 8 of these patients (15%) were treated with a short course of steroids. One patient, whose skin test was negative, had an immediate anaphylactic reaction to ERIG that responded to parenteral therapy with epinephrine and hydrocortisone sodium succinate. Serum-sickness-like reactions were more frequent among females and over 21-year-olds but were exceedingly rare (0.086%) among children under 10 years of age.

Full text

PDF
736

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BALTAZARD M., BAHMANYAR M. Essai pratique du sérum antirabique chez les mordus par loups enragés. Bull World Health Organ. 1955;13(5):747–772. [PMC free article] [PubMed] [Google Scholar]
  2. HABEL K., KOPROWSKI H. Laboratory data supporting the clinical trial of anti-rabies serum in persons bitten by a rabid wolf. Bull World Health Organ. 1955;13(5):773–779. [PMC free article] [PubMed] [Google Scholar]
  3. HOSTY T. S., HUNTER F. R. Incidence of reactions to antirabies horse serum. Public Health Rep. 1953 Aug;68(8):789–791. [PMC free article] [PubMed] [Google Scholar]
  4. Helmick C. G., Johnstone C., Sumner J., Winkler W. G., Fager S. A clinical study of Merieux human rabies immune globulin. J Biol Stand. 1982 Oct;10(4):357–367. doi: 10.1016/s0092-1157(82)80013-9. [DOI] [PubMed] [Google Scholar]
  5. Lodmell D. L., Ewalt L. C. Immune sera and antiglycoprotein monoclonal antibodies inhibit in vitro cell-to-cell spread of pathogenic rabies viruses. J Virol. 1987 Oct;61(10):3314–3318. doi: 10.1128/jvi.61.10.3314-3318.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Phanuphak P., Khawplod P., Sirivichayakul S., Siriprasomsub W., Ubol S., Thaweepathomwat M. Humoral and cell-mediated immune responses to various economical regimens of purified Vero cell rabies vaccine. Asian Pac J Allergy Immunol. 1987 Jun;5(1):33–37. [PubMed] [Google Scholar]
  7. VEERARAGHAVAN N., SUBRAHMANYAN T. P. Value of antirabies vaccine with and without serum against severe challenges. Bull World Health Organ. 1960;22:381–391. [PMC free article] [PubMed] [Google Scholar]
  8. Wilde H., Chomchey P., Prakongsri S., Punyaratabandhu P. Safety of equine rabies immune globulin. Lancet. 1987 Nov 28;2(8570):1275–1275. doi: 10.1016/s0140-6736(87)91885-x. [DOI] [PubMed] [Google Scholar]
  9. Wilde H., Chomchey P., Prakongsri S., Puyaratabandhu P., Chutivongse S. Adverse effects of equine rabies immune gobulin. Vaccine. 1989 Feb;7(1):10–11. doi: 10.1016/0264-410x(89)90003-0. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES